News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Is AbbVie (ABBV) About to Deliver a Blow to Gilead (GILD)' Guidance?



8/7/2017 9:22:22 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
After boosting its full-year hepatitis C revenue guidance last month, Gilead Sciences' (NASDAQ:GILD) share price has been rallying. However, the Food and Drug Administration approved AbbVie's (NYSE:ABBV) next-generation hepatitis C drug Mavyret this week, and AbbVie has priced it to sell. Could Mavyret deliver a big blow to Gilead Sciences' hopes for higher hepatitis C sales?

Read at Motley Fool


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES